A new review pooled 89 studies to estimate how common MRSA is among human S. aureus samples in Iran. The combined estimate was 46.4 percent, meaning roughly one in two S. aureus isolates was methicillin-resistant. After adjusting for possible publication bias, the estimate dropped to 38.8 percent. The review also looked at the genetic types of MRSA. Type III, often linked to hospital settings, was the most common at 44 percent, while type IVb was found in 6 percent. The authors say this points to a substantial MRSA burden and a dominance of hospital-associated strains in Iran. The main caution is that the studies varied widely, which makes the pooled numbers less certain. This is a summary of published data, not a new treatment trial, so it does not test any drug or prevention strategy. Readers should see it as a broad picture of MRSA in one country, not a personal risk estimate. For questions about your own risk or care, talk with a doctor.
MRSA accounts for 46.4% of S. aureus isolates in Iran, SCCmec III predominatesMRSA Rates In Iran Hit 46 Percent, Review Finds
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This meta-analysis pooled 89 studies of human S. aureus isolates in Iran to estimate MRSA prevalence and SCCmec distribution. The pooled prevalence of MRSA was 46.4% (95% CI: 43.6-49.3%), with considerable heterogeneity across studies (I= 96.9%, P < 0.001). Trim-and-fill adjustment for potential publication bias reduced the estimate to 38.8%.
Among SCCmec types, type III was the most prevalent at 44%, while type IVb was 6%. The authors note that these findings highlight a substantial MRSA burden and the predominance of hospital-associated clones in Iran.
The main limitation is the considerable heterogeneity among included studies, which the authors state warrants cautious interpretation of pooled estimates. No safety data, funding information, or conflicts of interest were reported.
For clinicians, these estimates describe the regional epidemiology of MRSA in Iran and may inform local infection control and empiric therapy considerations, but the wide variation between studies means the pooled figure should not be applied directly to individual patients or specific settings without local data.
How this fits prior evidence
This meta-analysis extends prior coverage of MRSA epidemiology by providing a pooled prevalence estimate for Iran, where MRSA accounted for 46.4% of human S. aureus isolates. It contrasts with the 7.3% MRSA carriage prevalence reported in Ethiopia, though the Iranian estimate reflects clinical isolates rather than carriage. The SCCmec III predominance at 44% is consistent with hospital-associated strains, complementing the narrative review on CRISPR strategies for MRSA biofilms, which addressed treatment approaches rather than epidemiology.
Common questions
How common is MRSA in Iran?
A review of 89 studies estimated that 46.4 percent of human S. aureus samples in Iran were MRSA. After adjusting for possible publication bias, the estimate was 38.8 percent. The authors note wide differences between studies, so the exact figure is uncertain.
What is SCCmec type III?
SCCmec is a genetic marker used to classify MRSA strains. In this review, type III was the most common at 44 percent. Type III is often linked to hospital-associated infections. Type IVb was much less common at 6 percent.
Does this review test a treatment for MRSA?
No. This is a meta-analysis of 89 studies that measured how common MRSA is and which strain types circulate. It did not test any drug, vaccine, or prevention method. It cannot say what treatment works best.
Why should I be cautious about these numbers?
The review found considerable heterogeneity, meaning the included studies differed a lot in their methods and populations. That makes the pooled estimate less precise. The authors say the numbers should be interpreted with caution.
More on Methicillin-resistant Staphylococcus aureus
View Original Abstract ↓
Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals
New data shows prevalence of fungal infections in HIV patients
Related in Infectious Disease
From Other Specialties
